Brief Summary

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with prostate cancer. It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

2,000

participants targeted

Target at P75+ for all trials

Timeline

1mo left

Started Jul 2025

Shorter than P25 for all trials

Geographic Reach

1 country

24 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

1 year study duration

Study Progress90%

Jul 2025Jul 2026

Study Start

First participant enrolled

July 21, 2025

Completed

2 months until next milestone

First Submitted

Initial submission to the registry

September 4, 2025

Completed

7 months until next milestone

First Posted

Study publicly available on registry

March 20, 2026

Completed

4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 21, 2026

Expected

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 21, 2026

Last Updated

April 17, 2026

Status Verified

February 1, 2026

Enrollment Period

1 year

First QC Date

September 4, 2025

Last Update Submit

April 14, 2026

Conditions

Prostate Cancer Prostate Cancer (Diagnosis)Prostate Cancer (Post Prostatectomy)Prostate Cancer Patients Treated by Radiotherapy Prostate Cancer Metastatic Prostate Cancer (Adenocarcinoma)

Keywords

oncologypatient outcomeProstate CancerProstate Cancer in Algerian patientsObservational StudyRetrospective dataTreatment strategiesDiagnostic approachesClinical characteristicsEpidemiological dataDemographic dataCross-sectional studyReal-world dataAlgeriaAlgerian Study

Outcome Measures

Primary Outcomes (8)

Socio-demographic characteristics of patients with prostate cancer in Algeria
Frequency (%) of sociodemographic characteristics of patients with prostate cancer in Algeria, including age at diagnosis, marital status, and socioeconomic level.
At Baseline ( Initial visit )
Personal and family history of cancer
Frequency (%) of patients with personal and family history of cancer.
At Baseline (Initial Visit)
Environmental and occupational exposures
Frequency (%) of patients with environmental or occupational exposures.
At Baseline (Initial visit)
Smoking history
Frequency (%) of patients according to smoking status (current, former, never).
At Baseline (Initial visit)
Alcohol consumption
Frequency (%) of patients according to alcohol consumption (yes/no).
At Baseline (Initial visit)
Initial symptoms and circumstances of diagnosis
Frequency (%) of patients according to type of initial symptoms and circumstances of diagnosis.
At Baseline (Initial visit)
International Prostate Symptom Score (IPSS)
Distribution of patients according to the International Prostate Symptom Score (IPSS) at baseline. The IPSS is a validated questionnaire assessing the severity of lower urinary tract symptoms, with a total score ranging from 0 to 35, where higher scores indicate more severe (worse) symptoms.
At Baseline (Initial visit)
Evolutionary status of patients
Frequency (%) of patients according to disease status (in remission or with disease progression).
At Baseline (Initial visit)

Secondary Outcomes (13)

Diagnosis by PSA testing
At Baseline (Initial visit)
Diagnosis by imaging
At Baseline (Initial visit)
Diagnosis by biopsy
At Baseline (Initial visit)
Time from symptom onset to first medical consultation
At Baseline (Initial visit)
Time from first consultation to confirmed diagnosis
At Baseline (Initial visit)
+8 more secondary outcomes

Eligibility Criteria

Age19 Years+

Sexmale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

Patients with histologically and/or biologically confirmed prostate cancer, followed in the participating centers.

You may qualify if:

Patients aged 19 years and older.
Diagnosis of prostate cancer confirmed histologically and/or biologically.
Patients followed in the participating oncology departments.
Written informed consent obtained.
Histological types other than carcinoma
Secondary tumors
Participation in an interventional study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Société Algérienne de Formation et Recherche en Oncologielead
Ipsencollaborator
ES Clinical Researchcollaborator
Astellas Pharma Inccollaborator

Study Sites (24)

CAC Adrar - Oncology Department

Adrar, Algeria, 01000, Algeria

NOT YET RECRUITING

CAC Adrar - Radiotherapy Department

Adrar, Algeria, 01000, Algeria

NOT YET RECRUITING

CAC BLIDA - Oncology Department